Laboratory tests

Schiff's Diseases of the Liver

Volumn , Issue , 2011, Pages 17-43

  Herlong, H Franklin ^a   Mitchell Jr , Mack C ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

AST and ALT, liver cells; Bilirubin metabolism; Drug induced liver injury (DILI); Hepatic dysfunction; Hepatitis C, ALT, AST levels; Isocitrate dehydrogenase (ICDH); Laboratory tests; Liver biopsy; Serum aminotransferases; Serum enzyme tests

Indexed keywords

EID: 84886580385     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119950509.ch2     Document Type: Chapter

References (109)

1. Diehl AM, Boitnott J, Van Duyn MA, et al. Relationship between pyridoxal 5'-phosphate deficiency and aminotransferase levels in alcoholic hepatitis. Gastroenterology 1984;86:632.
2. Matloff DS, SelingerMJ, Kaplan MM. Hepatic transaminase activity in alcoholic liver disease. Gastroenterology 1980;78:1389.
3. Price C, Alberti K. Biochemical assessment of liver function. In: Wright JG, Alberti MM, Karran S, Millward-Sadler GH, eds. Liver and Biliary Diseases - pathophysiology, diagnosis, management. London: WB Saunders, 1979:381.
4. Inglesby T, Rai R, Astemborski J, Gruskin L, Nelson K. A prospective, community-based evaluation of liver enzymes in individuals with hepatitis c after drug use. Hepatology 1999;29:590.
5. Karmen A, Wroblewksi F, LaDue J. Transaminase activity in human blood. J Clin Invest 1955;34:126.
6. Siest G, Schelele F, Marie-Madaleine G, et al. Aspartate aminotransferaser and alanine aminotransferase activities in plasma: statistical distributions, individual variations, and reference values. Clin Chem 1975;21:1077.
7. Sherman K. Alanine aminotransferase in clinical practice. Arch Intern Med 1991;151:260.
8. Piton A, Poynard T, Imbert-Bismut F, et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. Hepatology 1998;27:1213.
9. Pratti D, Taloli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Int Med 2002;137:1.
10. Lee JK, Shim JH, Lee HC, et al. Estimation of the healthy upper limites for serum alanine aminotranferase in asin populationswith norman liver hepatology. Hepatology 2010;51:1577.
11. Lok A, McMahon B. Chronic hepatitis B. Hepatology 2007;45:507.
12. Liaw Y-F, Leung N, Kao J-H, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008;2:263.
13. Marcellin P, Dusheiko G, Zoulim F, et al. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50: 227.
14. Keeffe E, Dieterich D, Han S, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastro Hep 2008;6:1315.
15. Kim HC, Nam CM, Jee SH, et al. Normal serum aminotransferase concentration and risk of mortality from liver disease: prospective cohort study. Br Med J 2004;doi:10.1136/bmj.38050.593634.63: 1-6.
16. Yagura M, Tanaka A, Kamitsukasa H, et al. Re-evaluation of the serum alanine aminotransferase upper normal limit in chronic hepatitis C patients. Intern Med 2010;49:525.
17. Cohen JA, Kaplan MM. The SGOT/SGPT ratio: an indicator of alcoholic liver disease. Dig Dis Sci 1979;24:8335.
18. Sheth SG, Flamm SL, Gordon FD, et al. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998;93:44.
19. Reedy DW, Loo AT, Levine RA. AST/ALT ratio greater than 1 is not diagnostic of cirrhosis in patients with chronic hepatitis C. Dig Dis Sci 1998;43:2156.
20. Giannini E, Botta F, Fasoli A, et al. Progressive liver functional impairment is associated with an increase in AST/ALT ratio. Dig Dis Sci 1999;44:1249.
21. Park GJ, Lin BP, NguMC, et al. Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis? J Gastroenterol Hepatol 2000;15:386.
22. Tameda M, Shirak K, Ooi K, et al. Aspartate aminotransferase- immunoglobulin complexes in patients with chronic liver disease. World J Gastroenterol 2005;11:1529.
23. Nathwani RA, Pais S, Reynolds TB, et al. Serum alanine aminotransferase in skeletal muscle diseases. Hepatology 2005;41:380.
24. Pratt D, Kaplan M. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000;342:1266.
25. Kaplan M. Alanine aminotransferase levels: what's normal. Ann Int Med 2002;137:49.
26. Aragon G, Younossi ZM. When and how to evaluate mildly elevated liver enzymes in apparently healthy patients. Cleveland Clin Med 2010;77:195.
27. Kim WR, Flamm S, DeBisceglie A, Bodenheimer H Jr. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 2008;47:1363.
28. Ruhl C, Everhard J. Elevated serumalanine aminotransferase and γ- glutamyltransferase and mortality in the United States population. Gastroenterology 2009;136:477.
29. Lee TH, Kim W, Benson J, Therneau T, Melton L.J. Serum aminotransferase activity and mortality risk in a United States community. Hepatology 2008;47:880.
30. Ioannao G, Weiss N, Boyko E, Mozaffarian D, Lee SP. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 2006;43:1145.
31. Le Couteur D, Blyth F, Creasey H, et al. The association of alanine transaminase with aging, frailty, and mortality. J Gerontol A Biol Sci Med Sci 2010;65:712.
32. Jenkins W, Rosalki S, Foo Y, et al. Serum glutamate dehydrogenase is not a reliable marker of liver cell necrosis in alcoholics. J Clin Pathol 1982;35:207.
33. Chung YH, Jung SA, Song BC, et al. Plasma isocitrate dehydrogenase as a marker of centrilobular hepatic necrosis in patients with hyperthyroidism. J Clin Gastroenterol 2001;33:118.
34. Khayrollah A, Al-Tamer M, Taka M, et al. Serum alcohol dehydrogenase activity in liver diseases. Ann Clin Biochem 1982;19:35.
35. Naryham, S. Serum alkaline phosphatase isoenzymes as markers of liver disease. Ann Clin Lab Sci 1991;21:12.
36. Harris H. The human alkaline phosphatases: what we know and what we don't know. Clin Chim Acta 1989;186:133.
37. Henny J, Shiele F. Alkaline phosphatase. In: Siest G, Henny J, Shiele F, Young DS, eds. Interpretation of Clinical Laboratory Tests. Reference values and their biological variation. Foster City, CA: Biomedical Publications, 1985: 96-118.
38. Alvaro D, Benedetti A, Marucci L, et al. The function of alkaline phosphatase in the liver: regulation of intrahepatic biliary epithelium secretory activities in the rat. Hepatology 2000;32:174.
39. Kaplan M. Alkaline phosphatase. Gastroenterology 1972;62:452.
40. Bamford KF, HarrisH, Luffman J, et al. Serum-alkaline-phosphatase and the ABO blood groups. Lancet 1965;1:530.
41. Heino AE, Jokipii SG. Serum alkaline phosphatase levels in the aged. Am Med Intern Med 1962;51:105.
42. Siraganian PA, Mulvihill JJ, Mulivor RA, et al. Benign familial hyperphosphatasemia. JAMA 1989;261:1310.
43. Kaplan MM, Rogers L. Separation of serum alkaline phosphatase isoenzymes by polyacrylamide gel electrophoresis. Lancet 1968;2:102.
44. Kaplan MM, Righetti A. Induction of rat liver alkaline phosphatase: themechanism of the serum elevation in bile duct obstruction. J Clin Invest 1970;49:508.
45. Seetharam S, Sussman NL, Komoda T, Alpers DH. The mechanism of elevated alkaline phosphates activity afterbile duct ligation in the rat. Hepatology 1986;6:374.
46. Debroe ME, Roels F, Nouwen EJ, et al. Liver plasma membrane is the source of high-molecular-weight alkaline phosphatase in human serum. Hepatology 1985;5:118.
47. Margulis SJ, Honig CL, Soave R, et al. Biliary tract obstruction in the acquired immunodeficiency syndrome. Ann Intern Med 1986;105:207.
48. Brensilver HL, Kaplan MM. Significance of elevated liver alkaline phosphatase in serum. Gastroenterology 1975;68:1556.
49. Shaver WA, Bhatt H, Combes B. Low serum alkaline phosphatase activity in Wilson's disease. Hepatology 1986;6:859.
50. Wilson RA, Clayson KJ, Leon S. Unmeasurable serum alkaline phosphatase activity in Wilson's disease associated with fulminant hepatic failure and hemolysis. Hepatology 1987;7:613.
51. Righetti ABB, Kaplan MM. Disparate responses of serum and hepatic alkaline phosphatase and 5'-nucleotidase to bile duct obstruction in the rat. Gastroenterology 1972;62:1034.
52. Eshchar J, Ruzki C, Zimmerman HJ, et al. Serum levels of 5'- nucleotidase in disease. Am J Clin Pathol 1967;47:598.
53. Rutenberg AM, Goldbarg JA, Pineda GP, et al. Serum γ-glutamyl transpeptidase activity in hepatobiliary pancreatic disease. Gastroenterology 1963;45:43.
54. Sotil E, Jensen D. Serum enzymes associated with cholestasis. Clin Liver Dis 2004;8:41.
55. Rollason JG, Pincharle G, Robinson D, et al. Serumgamma-glutamyl transpeptidase in relation to alcohol consumption. Clin Chim Acta 1972;39:75.
56. Rosalki S, Rau D. Serum gamma-glutamyl transpeptidase activity in alcoholism. Clin Chim Acta 1972;39:41.
57. Selinger MJ, Matloff DS, Kaplan MM, et al. γ-Glutamyl transpeptidase activity in liver disease: serum elevation is independent of hepatic GGTP activity. Clin Chim Acta 1982;125:283.
58. Burrows S, Feldman W, McBride F, et al. Serum gamma-glutamyl transpeptidase: evaluation in screening of hospitalized patients. Am J Clin Pathol 1975;64:311.
59. Rutenberg AM, Banks BM, Pineda EP, et al. A comparison of serum aminopeptidase and alkaline phosphatase in the detection of hematobiliary disease in anicteric patients. Ann Intern Med 1964;61:50.
60. Triger DR, Wright R. Hypergammaglobulinemia in liver disease. Lancet 1973;1:1494.
61. Rothschild MA, Oratz M, Zimmon D, et al. Albumin synthesis in cirrhotic subjects studied with carbonate 4C. J Clin Invest 1969;48:344.
62. Rothschild MA, Oratz M, Schreiber SS. Serum albumin. Hepatology 1988;8:385.
63. Oratz M, Rothschild MA, Schreiber SS, et al. The role of the urea cycle and polyamines in albumin synthesis. Hepatology 1983;3:567.
64. Jefferson DM, Reid LM, GiambroneMA, et al. Effects of dexamethasone on albumin and collagen gene expression in primary cultures of adult rat hepatocytes. Hepatology 1985;5:14.
65. Bernau D, Rogier E, Feldmann G, et al. Decreased albumin and increased fibrinogen secretion by single hepatocytes from rats with acute inflammatory reaction. Hepatology 1983;3:29.
66. Dinarello C. Interleukin-1 and the pathogenesis of the acute phase response. N Engl J Med 1984;311:1413.
67. van Zanten SJO, Depla ACTM, Dekker PC, et al. The clinical importance of routine measurement of liver enzymes, total protein, and albumin in a generalmedicine outpatient clinic: a prospective study. N Engl J Med 1992;40:53.
68. Olson JP, Miller LL, Troup SB. Synthesis of clotting factors by the isolated perfused rat liver. J Clin Invest 1966;45:690.
69. Mattii R, Ambrus JL, Sokal JE, et al. Production of members of the blood coagulation and fibrinolysin systems by the isolated perfused liver. Proc Soc Exp Biol Med 1964;116:69.
70. Rapaport SI, Ames SB, Mikkelsen S, et al. Plasma clotting factors in chronic hepatocellular disease. N Engl J Med 1960;263:278.
71. Liebman HA, Furie BC, Furie B, et al. Hepatic vitamin K-dependent carboxylation of blood-clotting proteins. Hepatology 1982;2:488.
72. Blanchard RA, Furie BC, Jorgensen M, et al. Acquired vitamin Kdependent carboxylation deficiency in liver disease. N Engl J Med 1981;305:242.
73. Weitz IC, Liebman HA. Des-γ-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology 1993;18:990.
74. Liebman HA, Furie BC, Tong MJ, et al. Des-γ-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984;310:1427.
75. Suehiro T, Sugimachi K, Matsumata T, et al. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma: comparison with alpha-fetoprotein. Cancer 1994;73:2464.
76. Lester R, Schmid R. Bilirubin metabolism. N Engl J Med 1964;270: 779.
77. Robinson S, Lester R, Crigler JF Jr, et al. Early-labeled peak of bile pigment in man: studies with glycine-14C and delta aminolevulinic acid-3H. N Engl J Med 1967;277:1323.
78. Landow SA, Callahan EWJr, Schmid R. Catabolism of heme in vivo: comparison of the simultaneous production of bilirubin and carbon monoxide. J Clin Invest 1970;49:914.
79. Tenhunen R, Ross ME, Marver HS, et al. Reduced nicotinamideadenine dinucleotide phosphate-dependent biliverdin reductase: partial purification and characterization. Biochemistry 1970;9:288.
80. Scharschmidt BF, Waggoner JG, Berk PD. Hepatic organic anion uptake in the rat. J Clin Invest 1975;56:1280.
81. Zieve L, Hill E, Hanson M, et al. Normal and abnormal variations and clinical significance of the one-minute and total serum bilirubin determinations. J Lab Clin Med 1951;38:446.
82. Blanckaert N, Kabra PM, Farina FA, et al. Measurement of bilirubin and its monoconjugates and diconjugates in human serum by alkaline methanolysis and high-performance liquid chromatography. J Lab Clin Med 1980;96:198.
83. Weiss JS, Gautam A, Lauff JJ, et al. The clinical importance of aprotein-bound fraction of serum bilirubin in patients with hyperbilirubinemia. N Engl J Med 1983;309:147.
84. Raymond GD, Galambos JT. Hepatic storage and excretion of bilirubin in man. Am J Gastroenterol 1971;55:135.
85. Schmid R, Diamond I, Hammaker L, et al. Interaction of bilirubin with albumin. Nature 1965;206:1041.
86. Hardison WG, Lee FI. Prognosis in acute liver disease of the alcoholic patient. N Engl J Med 1966;275:61.
87. Lau H, Man K, Fan SCW, et al. Evaluation of preoperative hepatic function in patients with hepatocellular carcimona undergoing hepatectomy. Br J Surg 1997;84:1255.
88. Sakka, S. Assessing liver function. Curr Opin Crit Care 2007;13:207.
89. Oellerich M, Armstrong VW. The MEGX test: a tool for the real-time assessment of hepatic function. Ther Drug Monit 2001;23:81.
90. Shiffman M, Fisher R, Sanyal A, et al. Hepatic lidocaine metabolism and complications of cirrhosis. Transplantation 1993;55:830.
91. Shiffman M, Luketic V, Sanyal A, et al. Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis. Hepatology 1994;19:933.
92. Everson G, Hiffman M, Morgan T, Sterling R, Wagners D. Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial. Aliment Pharmacol Ther 2008;29:589.
93. Botta F, Gianni E, Romagnoli P, et al. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut 2003;52:134.
94. Renner E, Wietholtz H, Huguenin P, et al. Caffeine: a model compound for measuring liver function. Hepatology 1984;4:38.
95. Jost G, Wahllander A, vonMandach U, et al. Overnight salivary caffeine clearance: a liver function test suitable for routine use. Hepatology 1987;7:338.
96. Tarantion G, Conca P, Capone D, Gentile A. Reliability of total overnight salivary caffeine assessment (TOSCA) for liver function evaluation in compensated cirrhotic patients. Eur J Clin Pharm 2006;62:605.
97. Joeres R, Klinker H, Heusler H, et al. Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver disease. Hepatology 1988;8:575.
98. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastorenterology 2005;128:343.
99. Parkes J, Guha IN, Roderick P, et al. Enhanced liver fibrosis (ELF) test accurately identifies liver cirrhosis in patients with chronic hepatitis C. J Viral Hepat 2010;18:23.
100. Triger DR, Wright R. Hypergammaglobulinemia in liver disease. Lancet 1973;1:1494.
101. Machlachlan MJ, Rodnan GP, Cooper WM, et al. Chronic active (lupoid) hepatitis. Ann Intern Med 1965;62:425.
102. Nathwani R, Kumar S, Reynolds T, Kaplowitz N. Marked elevation in serumtransaminases: an atypical presentation of choledocholithiasis. Am J Gastroenterol 2005;100:295.
103. Kaplan M. Evaluation of hepatobiliary diseases. In: Stein JH, ed. Internal Medicine. Boston: Little, Brown, 1998: 443.
104. Clarke LC, Beck EJ. Plasma "alkaline" phosphatase activity, I: normative data for growing children. J Pediatr 1950;36:335.
105. Wolf PL. Clinical significance of an increased or decreased serum alkaline phosphatase level. Arch Pathol Lab Med 1978;102:497.
106. Whitefield JB, Pounder RE, Neale G, et al. Serum γ-glutamyl transpeptidase activity in liver disease. Gut 1972;13:702.
107. Putnam FW. The Proteins, 2nd edn, Vol. 1. Orlando: Academic Press, 1975: 18.
108. Ostrow JD, Aria I, Carey M, Forker L. Unit 1. Hepatic excretory function: undergraduate teaching project. Baltimore, MD: American Gastroenterological Association, Milner-Fenwick Slides Company.
109. Crawford J, Hauser S, Gollan J. Formation, hepatic metabolism, and transport of bile pigments: a status report. Semin Liver Dis 1988;8:105.